What is WIPO ST.26 and how does it differ from WIPO ST.25?
WIPO ST.26 is a new standard for the presentation of nucleotide and amino acid sequence listings in patent applications. It replaces WIPO ST.25 for applications filed on or after July 1, 2022. The MPEP states: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1,…
Read MoreWhat are the WIPO ST.26 requirements for applications filed on or after July 1, 2022?
The MPEP 2422.06 section includes an important editor’s note regarding applications filed on or after July 1, 2022: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412 – 2419 for…
Read MoreHow do the requirements for sequence listings differ between WIPO ST.25 and WIPO ST.26?
The requirements for sequence listings differ significantly between WIPO ST.25 and WIPO ST.26. WIPO ST.25 was the standard used for applications filed before July 1, 2022, while WIPO ST.26 applies to applications filed on or after that date. The MPEP notes: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications…
Read MoreWhen did the transition from WIPO ST.25 to WIPO ST.26 occur?
The transition from WIPO ST.25 to WIPO ST.26 for sequence listings in patent applications occurred on July 1, 2022. As stated in MPEP § 2431: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” For applications…
Read MoreHow does the change from WIPO ST.25 to ST.26 affect existing patent applications?
The transition from WIPO ST.25 to ST.26 primarily affects new patent applications filed on or after July 1, 2022. As stated in MPEP § 2431: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” Existing applications…
Read MoreWhat are the key differences between WIPO ST.25 and WIPO ST.26 for sequence listings?
While MPEP § 2431 doesn’t directly compare WIPO ST.25 and ST.26, it indicates a significant change in requirements: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.” Key differences include: Format: ST.26 uses XML format, while ST.25 used a text-based format Scope: ST.26…
Read MoreWhen are WIPO ST.25 sample statements not applicable?
According to the MPEP, WIPO ST.25 sample statements are not applicable to certain patent applications. Specifically: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” For applications filed on or after July 1, 2022, applicants should…
Read MoreWhat changes have been made to the “Sequence Listing” requirements for applications filed on or after July 1, 2022?
For patent applications filed on or after July 1, 2022, there have been significant changes to the “Sequence Listing” requirements. The MPEP section 2424.01 includes an important editor’s note: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined…
Read MoreWhen did the requirements for Sequence Listings change?
The requirements for Sequence Listings in patent applications changed on July 1, 2022. This is clearly stated in the MPEP: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]” For applications filed before July…
Read MoreWhen did the requirements for nucleotide and amino acid sequence data change?
The requirements for nucleotide and amino acid sequence data changed on July 1, 2022. The MPEP section notes: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412 – 2419 for…
Read More